A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor Resistance.
Kinase enzymes are an important class of drug targets, particularly in cancer. Cell-based kinase assays are needed to understand how potential kinase inhibitors act on their targets in a physiologically relevant context. Current cell-based kinase assays rely on antibody-based detection of endogenous...
Main Authors: | Steven B Ouellette, Brett M Noel, Laurie L Parker |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5012566?pdf=render |
Similar Items
-
Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion
by: Kerstin Cornils, et al.
Published: (2017-07-01) -
Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion
by: Cornils, Kerstin, et al.
Published: (2017) -
Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
by: Mian Afsar, et al.
Published: (2012-09-01) -
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
by: Octavian Bucur, et al.
Published: (2013-01-01) -
Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
by: Francesca Carofiglio, et al.
Published: (2020-06-01)